Preliminary restructuring measures

The Company, together with the administrator, has prepared the following preliminary restructuring measures:

• Offer unsecured creditors a 30% composition (i.e. a 70% debt write-off)
• Offer Rosland Nordic AB, which has provided a secured bridge financing amounting to approximately SEK 1 million, to convert debt into shares in the Company
• Investigate the possibilities for a share issue to existing shareholders who have expressed their support for participating in such a rights issue
• Implement operational restructuring measures in the revised business plan and complete the US launch

The Company's assessment is that the above measures mean that the Company's operations will be able to be conducted with a positive result from the end of the second quarter of 2025. Furthermore, the assessment is made that a debt settlement in combination with new share issues and operational reconstruction measures will ensure that the Company's operations can be continued.

Forward-looking projections

The Company has also, based on the above measures, prepared a liquidity forecast for 2025. The forecast, which has been reviewed by the administrator, shows that the Company, through the corporate restructuring, together with the payment ban for pre-petition debts and with the support of the state wage guarantee, will have the necessary liquidity to carry out the restructuring. The liquidity forecast also shows that positive cash flow will be achieved from May 2025 onwards. Note that the forecast also includes the Company's subsidaries in the US. In this regard, it should be noted that the Company has received bridge financing amounting to approximately SEK 1 million and that it should be added that the Company has ongoing sales revenue. The Company's growth rate and forward-looking forecasts further show that the Company in 2025 is expected to achieve a turnover of SEK 45 million and thus generate a positive result and that the Company is expected to achieve profitability from May 2025. Growth in the Company's turnover in 2025 is expected to amount to approximately SEK 33.7 million. The corresponding growth for earnings is expected to amount to approximately SEK 63.8 million for EBIT and SEK 39.8 million for EBITDA.

Termination of the corporate restructuring

At the creditors' meeting on March 26, 2025, the district court decided that the corporate restructuring may continue until June 13, 2025. If no request for an extension has been received by June 13, 2025, the district court will then decide that the corporate restructuring will end.  A corporate restructuring may not last longer than a total of twelve months, unless the court has previously decided on plan negotiations. As communicated earlier, the restructuring is expected to be completed within three to six months from the application for corporate restructuring.

Complete documents relating to the corporate restructuring are available on the Company's website, www.peptonicmedical.se.

For further information contact:

Anna Linton, CEO Peptonic Medical AB
Email: anna.linton@peptonicmedical.se
Telephone: +46 70-244 92 07

About PEPTONIC Medical AB                                                                                                                

PEPTONIC medical AB (publ) is a pioneering Swedish Medical Device company specializing in the development and sale of clinically proven self-care products for women's intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic's growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.

The Company is headquartered in Stockholm, Sweden, and operates the subsidiaries, Peptonic Medical Inc and Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.